Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson’s disease…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease
Objective: To evaluate the acceptability, feasibility, safety and effectiveness of a novel remotely delivered Parkinson’s care pathway. Background: Current care pathways for people with Parkinson’s…Neuroprotective Epigenetic and DNA-Repair Molecular Mechanisms of Acetyl-L-Carnitine and Astaxanthin Against 6-OHDA Induced Parkinsonism in Aged Rats
Objective: Present study was designed to delineate the neuroprotective epigenetic and DNA-damage-repair molecular mechanisms of acetyl-L-carnitine (ALC) and astaxanthin (ASX) against 6-OHDA-induced neurotoxicity in aged…LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset
Objective: To investigate the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation on the anti-parkinsonian action of a low dose of…Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study
Objective: To assess the effects of opicapone 50 mg on the pharmacokinetics (PK) of levodopa (LD) and its metabolite, 3-O-methyldopa (3-OMD), when administered with oral…Findings from a Community-based LOUD Crowd® Program for People with Parkinson Disease
Objective: SPEAK OUT!® and LOUD Crowd® programs target the communicative functioning of people with Parkinson disease (PD). The current study includes findings from a year-long…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study
Objective: This study aimed to explore patients’ adherence to antiparkinsonian medication, and to determine factors associated with low adherence among Serbian PD patients. Background: Adherence…
- « Previous Page
- 1
- …
- 744
- 745
- 746
- 747
- 748
- …
- 1734
- Next Page »